PRMT5 and familial pancreatic carcinoma: Curiously, the addition of PRMT1 to PRMT5 inhibition in a pancreatic cancer cell line induces a synergistic increase in >2400 novel ASEs compared with PRMT5 or PRMT1 inhibitor alone.